Shandong Realcan Pharmaceutical Co Ltd (002589) — Tangible Net Worth Ratio
Shandong Realcan Pharmaceutical Co Ltd (002589) has a Tangible Net Worth Ratio of 90.7% as of March 2026. This metric is calculated by deducting intangible assets (CN¥504.89 Million) from net assets (CN¥5.44 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See Shandong Realcan Pharmaceutical Co Ltd book value and equity for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Shandong Realcan Pharmaceutical Co Ltd Tangible Net Worth Ratio (2008–2025)
This chart shows how Shandong Realcan Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 18 annual periods from 2008 to 2025. As of March 2026, the ratio stands at 90.7%, reflecting net assets of CN¥5.44 Billion with intangible assets of CN¥504.89 Million CNY. Also explore Shandong Realcan Pharmaceutical Co Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Shandong Realcan Pharmaceutical Co Ltd (2008–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Shandong Realcan Pharmaceutical Co Ltd from 2008 to 2025, covering 18 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Shandong Realcan Pharmaceutical Co Ltd stock valuation.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 90.2% | CN¥5.42 Billion | CN¥528.80 Million | CN¥14.37 Billion | ▼ -2.0 pp |
| 2024 | 92.3% | CN¥5.69 Billion | CN¥440.89 Million | CN¥16.01 Billion | ▲ +2.1 pp |
| 2023 | 90.2% | CN¥5.64 Billion | CN¥552.39 Million | CN¥16.71 Billion | ▲ +1.1 pp |
| 2022 | 89.1% | CN¥5.75 Billion | CN¥624.21 Million | CN¥18.33 Billion | ▼ -5.8 pp |
| 2021 | 95.0% | CN¥9.69 Billion | CN¥487.93 Million | CN¥26.40 Billion | ▼ -2.6 pp |
| 2020 | 97.6% | CN¥9.64 Billion | CN¥230.50 Million | CN¥31.29 Billion | ▼ -0.2 pp |
| 2019 | 97.9% | CN¥10.25 Billion | CN¥219.68 Million | CN¥32.47 Billion | ▼ -0.6 pp |
| 2018 | 98.5% | CN¥11.31 Billion | CN¥173.73 Million | CN¥34.84 Billion | ▼ -0.3 pp |
| 2017 | 98.7% | CN¥9.67 Billion | CN¥121.80 Million | CN¥26.98 Billion | ▼ -0.3 pp |
| 2016 | 99.0% | CN¥7.50 Billion | CN¥74.54 Million | CN¥15.66 Billion | ▲ +1.4 pp |
| 2015 | 97.6% | CN¥3.40 Billion | CN¥82.83 Million | CN¥8.86 Billion | ▲ +1.7 pp |
| 2014 | 95.8% | CN¥1.83 Billion | CN¥76.34 Million | CN¥5.68 Billion | ▼ -0.7 pp |
| 2013 | 96.5% | CN¥1.65 Billion | CN¥58.08 Million | CN¥4.45 Billion | ▲ +3.0 pp |
| 2012 | 93.5% | CN¥916.39 Million | CN¥59.72 Million | CN¥3.12 Billion | ▼ -0.8 pp |
| 2011 | 94.3% | CN¥817.11 Million | CN¥46.77 Million | CN¥2.22 Billion | ▲ +7.7 pp |
| 2010 | 86.5% | CN¥296.03 Million | CN¥39.87 Million | CN¥1.48 Billion | ▼ -8.0 pp |
| 2009 | 94.5% | CN¥234.18 Million | CN¥12.89 Million | CN¥1.04 Billion | ▲ +6.9 pp |
| 2008 | 87.6% | CN¥111.89 Million | CN¥13.85 Million | CN¥715.53 Million | — |